Provided by Tiger Trade Technology Pte. Ltd.

Olema Pharmaceuticals, Inc.

8.64
+0.10001.17%
Post-market: 8.670.0300+0.35%19:30 EDT
Volume:1.54M
Turnover:13.41M
Market Cap:753.04M
PE:-4.06
High:8.86
Open:8.59
Low:8.42
Close:8.54
52wk High:36.26
52wk Low:6.65
Shares:87.16M
Float Shares:71.89M
Volume Ratio:1.17
T/O Rate:2.15%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1289
EPS(LYR):-1.8700
ROE:-52.74%
ROA:-31.82%
PB:1.75
PE(LYR):-4.62

Loading ...

Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement With Bayer to Evaluate Op-3136 in Combination With Nubeqa® (Darolutamide) in Metastatic Castration-Resistant Prostate Cancer

THOMSON REUTERS
·
May 26

Olema Pharmaceuticals Inc - Study to Evaluate Op-3,136 and Darolutamide in 36 Patients, Initiation Expected in H2 2026

THOMSON REUTERS
·
May 26

Analysts Offer Insights on Healthcare Companies: IN8bio (INAB), Syndax Pharmaceuticals (SNDX) and Olema Pharmaceuticals (OLMA)

TIPRANKS
·
May 22

Olema Highlights Encouraging OP-3136 Phase 1 Oncology Results

TIPRANKS
·
May 22

Olema reports initial Phase 1 data for OP-3136 KAT6 inhibitor in solid tumors

Reuters
·
May 22

Olema Oncology Announces Encouraging Initial Clinical Data From the Phase 1 Study of Op-3136, a Kat6 Inhibitor, at 2026 Asco Annual Meeting

THOMSON REUTERS
·
May 22

J.P. Morgan Keeps Their Buy Rating on Olema Pharmaceuticals (OLMA)

TIPRANKS
·
May 19

LifeSci Capital Sticks to Their Buy Rating for Olema Pharmaceuticals (OLMA)

TIPRANKS
·
May 18

Citi opens ‘upside 90-day catalyst watch’ on Olema Oncology

TIPRANKS
·
May 14

Olema Pharmaceuticals Is Maintained at Buy by Guggenheim

Dow Jones
·
May 13

Stock Track | Olema Pharmaceuticals Plummets 5.01% Intraday Following Guggenheim Price Target Cut

Stock Track
·
May 13

Olema Pharmaceuticals: Citi’s Anupam Rama Reiterates Buy on Underappreciated Palazestrant Upside and Long-Term Pipeline Catalysts

TIPRANKS
·
May 13

Olema Oncology price target lowered to $35 from $38 at Guggenheim

TIPRANKS
·
May 13

Olema Pharmaceuticals: Differentiated KAT6i and Palazestrant Pipeline Catalysts Underpin Buy Rating

TIPRANKS
·
May 13

Analysts’ Top Healthcare Picks: Olema Pharmaceuticals (OLMA), Structure Therapeutics, Inc. Sponsored ADR (GPCR)

TIPRANKS
·
May 13

Olema Pharmaceuticals Q1 EPS $(0.52) Beats $(0.53) Estimate

Benzinga Earnings
·
May 12

Earnings Flash (OLMA) Olema Pharmaceuticals Posts Q1 Net Loss $0.52 a Share, vs. FactSet Est of $0.52 Loss

MT Newswires Live
·
May 12

Olema Pharmaceuticals Q1 net loss widens on higher R&D costs

Reuters
·
May 12

Press Release: Olema Oncology Reports First Quarter 2026 Financial and Operating Results

Dow Jones
·
May 12

Olema Pharmaceuticals Q1 Net Income USD -53.089 Million

THOMSON REUTERS
·
May 12